Prospective Analysis of Placenta Growth Factor (PlGF) Concentrations in the Plasma of Women with Normal Pregnancy and Pregnancies Complicated by Preeclampsia

Hypertension in Pregnancy

Volumn 23, Issue 1, 2004, Pages 101-111

  Krauss, Thomas ^a   Pauer, Hans Ulrich ^a   Augustin, Hellmut G ^b  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b TUMOR BIOLOGY CENTER   (Germany)

Author keywords

P1GF; Placenta growth factor; Prediction; Preeclampsia

Indexed keywords

GROWTH FACTOR; PLACENTAL GROWTH FACTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GESTATIONAL AGE; HELLP SYNDROME; HUMAN; HYPERTENSION; INFECTION; INTRAUTERINE GROWTH RETARDATION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MATERNAL HYPERTENSION; OUTCOMES RESEARCH; PREECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATION; PREGNANCY DIABETES MELLITUS; PREMATURE UTERINE CONTRACTION; PREMATURITY; PROSPECTIVE STUDY; PROTEINURIA; SENSITIVITY AND SPECIFICITY; THIRD TRIMESTER PREGNANCY; UTERUS CONTRACTION;

ADULT; BIOLOGICAL MARKERS; FEMALE; GERMANY; HELLP SYNDROME; HUMANS; MATERNAL WELFARE; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY PROTEINS; PREGNANCY TRIMESTER, SECOND; PREGNANCY TRIMESTER, THIRD; PROSPECTIVE STUDIES;

EID: 1842532440     PISSN: 10641955     EISSN: None     Source Type: Journal    
DOI: 10.1081/PRG-120028286     Document Type: Article

References (35)

1. Norwitz ER, Schust DJ, Fisher SJ. Implantation and the survival of early pregnancy. N Engl J Med 2001; 345:1400-1408.
2. Roberts JM. Preeclampsia: what we know and what we do not know. Semin Perinatol 2000; 24:24-28.
3. Lim KH, Zhou Y, Janatpour M, McMaster M, Bass K, Chun SH, Fisher S. Human cytotrophoblast differentiation/invasion is abnormal in pre-eclampsia. Am J Pathol 1997; 151:1809-1818.
4. Zhou Y, Fisher SJ, Janatpour M, Genbacev O, Dejana E, Wheelock M, Damsky CH. Human cytotrophoblasts adopt a vascular phenotype as they differentiate. A strategy for successful endovascular invasion? J Clin Invest 1997; 99:2139-2151.
5. Zhou Y, Damsky CH, Fisher SJ. Preeeclampsia is associated with failure of human cytotrophoblasts to mimic: a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome? J Clin Invest 1997; 99:2152-2164.
6. DiFederico E, Genbacev O, Fisher SJ. Preeclampsia is associated with widespread apoptosis of placental cytotrophoblasts within the uterine wall. Am J Pathol 1999; 155:293-301.
7. Kenny L, Baker PN. Maternal pathophysiology in pre-eclampsia. Bailliere's Best Pract Res Clin Obstet Gynaecol 1999; 13:59-75.
8. Roberts JM. Objective evidence of endothelial dysfunction in preeclampsia. Am J Kidney Dis 1999; 33:992-997.
9. Chien PF, Arnott N, Gordon A, Owen P, Khan KS. How useful is uterine artery Doppler flow velocimetry in the prediction of pre-eclampsia, intrauterine growth retardation and perinatal death? An overview. Br J Obstet Gynaecol 2000; 107:196-208.
10. Myatt L, Miodovnik M. Prediction of preeclampsia. Semin Perinatol 1999; 23:45-57.
11. Lyall F, Greer IA, Boswell F, Macara LM, Walker JJ, Kingdom JC. The cell adhesion molecule, VCAM-1, is selectively elevated in serum in pre-eclampsia: does this indicate the mechanism of leukocyte activation? Br J Obstet Gynaecol 1994; 101:485-487.
12. Daniel Y, Kupferminc MJ, Baram A, Geva E, Fait G, Lessing JB. A selective increase in plasma soluble vascular cell adhesion molecule-1 levels in preeclampsia. Am J Reprod Immunol 1999; 41:407-412.
13. Austgulen R, Lien E, Vince G, Redman CW. Increased maternal plasma levels of soluble adhesion molecules (ICAM-1, VCAM-1, E-selectin) in preeclampsia. Eur J Obstet Gynecol Reprod Biol 1997; 71:53-58.
14. Krauss T, Kuhn W, Lakoma C, Augustin HG. Circulating endothelial cell adhesion molecules as diagnostic markers for the early identification of pregnant women at risk for development of preeclampsia. Am J Obstet Gynecol 1997; 177:443-449.
15. Krauss T, Emons G, Kuhn W, Augustin HG. Predictive value of routine circulating soluble endothelial cell adhesion molecule measurements during pregnancy. Clin Chem 2002; 48:1418-1425.
16. Redman CW, Sacks GP, Sargent IL. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol 1999; 180:499-506.
17. Baker PN, Krasnow J, Roberts JM, Yeo KT. Elevated serum levels of vascular endothelial growth factor in patients with preeclampsia. Obstet Gynecol 1995; 86:815-821.
18. Kupferminc MJ, Daniel Y, Englender T, Baram A, Many A, Jaffa AJ, Gull I, Lessing JB. Vascular endothelial growth factor is increased in patients with preeclampsia. Am J Reprod Immunol 1997; 38:302-306.
19. Lyall F, Greer IA, Boswell F, Fleming R. Suppression of serum vascular endothelial growth factor immunoreactivity in normal pregnancy and in pre-eclampsia. Br J Obstet Gynaecol 1997; 104:223-228.
20. Clark DE, Smith SK, Licence D, Evans AL, Charnock-Jones DS. Comparison of expression patterns for placenta growth factor, vascular endothelial growth factor (VEGF), VEGF-B and VEGF-C in the human placenta throughout gestation. J Endocrinol 1998; 159:459-467.
21. Persico G. Placenta Growth Factor. In: Augustin HG, Iruela-Arispe LM, Rogers PAW, Smith SK, eds. Vascular Morphogenesis of the Female Reproductive System. New York, Springer/Birkhäuser: 2001:301-314.
22. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De Mol M, Wu Y, Bono F, Devy L, Beck H, Scholz D, Acker T, DiPalma T, Dewerchin M, Noel A, Stalmans I, Barra A, Blacher S, Vandendriessche T, Ponten A, Eriksson U, Plate KH, Fiodart JM, Schaper W, Charnock-Jones DS, Hicklin DJ, Herbert JM, Collen D, Persico MG. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001; 7:575-583.
23. Reuvekamp A, Velsing-Aarts FV, Poulina IE, Capello JJ, Duits AJ. Selective deficit of angiogenic growth factors characterises pregnancies complicated by preeclampsia. Br J Obstet Gynaecol 1999; 106:1019-1022.
24. Helske S, Vuorela P, Carpen O, Hornig C, Weich H, Halmesmaki E. Expression of vascular endothelial growth factor receptors 1, 2 and 3 in placentas from normal and complicated pregnancies. Mol Hum Reprod 2001; 7:205-210.
25. Torry DS, Wang HS, Wang TH, Caudle MR, Torry RJ. Preeclampsia is associated with reduced serum levels of placenta growth factor. Am J Obstet Gynecol 1998; 179:1539-1544.
26. Livingston JC, Chin R, Haddad B, McKinney ET, Ahokas R, Sibai BM. Reductions of vascular endothelial growth factor and placental growth factor concentrations in severe preeclampsia. Am J Obstet Gynecol 2000; 183:1554-1557.
27. Tidwell SC, Ho HN, Chiu WH, Torry RJ, Torry DS. Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclampsia. Am J Obstet Gynecol 2001; 184:1267-1272.
28. Tjoa ML, van Vugt JM, Mulders MA, Schutgens RB, Oudejans CB, van Wijk IJ. Plasma placenta growth factor levels in midtrimester pregnancies. Obstet Gynecol 2001; 98:600-607.
29. Livingston JC, Haddad B, Gorski LA, Neblett P, Ahokas RA, Ramsey R, Sibai BM. Placenta growth factor is not an early marker for the development of severe preeclampsia. Am J Obstet Gynecol 2001; 184:1218-1220.
30. Ong CY, Liao AW, Cacho AM, Spencer K, Nicolaides KH. First-trimester maternal serum levels of placenta growth factor as predictor of preeclampsia and fetal growth restriction. Obstet Gynecol 2001; 98:608-611.
31. Su YN, Lee CN, Cheng WF, Shau WY, Chow SN, Hsieh FJ. Decreased maternal serum placenta growth factor in early second trimester and preeclampsia. Obstet Gynecol 2001; 97:898-904.
32. Khaliq A, Li XF, Shams M, Sisi P, Acevedo CA, Whittle MJ, Weich H, Ahmed A. Localisation of placenta growth factor (PLGF) in human term placenta. Growth Factors 1996; 13:243-250.
33. Vourela-Vepsalainen P, Alfthan H, Orpana A, Alitalo K, Stenman UH, Halmesmaki E. Vascular endothelial growth factor is bound in amniotic fluid and maternal serum Hum Reprod 1999; 14:1346-1351.
34. Roberts JM. Preeclampsia is there value in assessing before clinically evident disease? Obstet Gynecol 2001; 98:596-599.
35. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP,: Sellke FW, Stillmann IE, Epstein FH, Sukhatme VP, Karumanchi SA. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111:649-658.